The treatment of intermittent claudication with beta-pyridyl carbinol over two years

Nye, Edwin R.; Macbeth, W. A. A. G.

doi:10.1016/0021-9150(73)90138-x

Cited by 6 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The groups had similar responses to the quality-of-life questionnaire. • In the trial by Nye et al (28), the use of β-pyridyl carbinol, a substance related to nicotinic acid, resulted in no significant difference in walking distance. A similar result occurred with the use of probucol and cholestyramine in the PQRST trial.…”

Section: Lipid-lowering Trials On Functional Capacity and Symptom Reliefmentioning

confidence: 97%

“…CLAS, PQRST, and the trial by Nye examined the effect of lipid lowering on nonfatal cardiovascular events and mortality. All of these studies failed to demonstrate a statistically significant difference in mortality between the treatment and control groups (1,22,28). A review by Leng et al (21) summarized the mortality data in these three trials.…”

Section: Cardiovascular Events and Mortality In Treatment Of Padmentioning

confidence: 99%

See 1 more Smart Citation

Lipid-Lowering Therapy in Patients with Peripheral Arterial Disease

Ebrahimi¹,

Saleh²,

Toggart³

et al. 2004

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

Peripheral arterial disease (PAD) is a prevalent, chronic, and progressive atherosclerotic disease process involving the conduit vessels of the extremities. Most patients who present with objective signs of PAD are asymptomatic. These patients are at an increased risk of dying from cardiovascular events. Lipid management is the mainstay of risk-factor modification for patients with cardiovascular disease. Some evidence suggests that hypocholesterolemic drugs may halt the progression of atherosclerotic peripheral vascular disease. More recently, treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors have demonstrated improved function in patients with symptomatic peripheral vascular disease. This paper reviews the role of lipid therapy in patients with peripheral arterial disease with focus on functional improvement and symptomatic relief based on the available data.

show abstract

Section: Lipid-lowering Trials On Functional Capacity and Symptom Reliefmentioning

confidence: 97%

Section: Cardiovascular Events and Mortality In Treatment Of Padmentioning

confidence: 99%

Lipid-Lowering Therapy in Patients with Peripheral Arterial Disease

Ebrahimi¹,

Saleh²,

Toggart³

et al. 2004

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Lipid-lowering for lower limb atherosclerosis

Price

Jepson

1998

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Lipid-lowering for peripheral arterial disease of the lower limb

Aung

Maxwell

Jepson

et al. 2007

Cochrane Database of Systematic Reviews

145

View full text Add to dashboard Cite

Analysis 1.1. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 1 All-cause mortality.. .. Analysis 1.2. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 2 Total cardiovascular events. Analysis 1.3. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 3 Fatal cardiovascular.. .. Analysis 1.4. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 4 Non-fatal cardiovascular events. Analysis 1.5. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 5 Total coronary.. .. .. Analysis 1.6. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 6 Fatal coronary event.. .. Analysis 1.7. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 7 Non-fatal coronary event.. Analysis 1.8. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 8 Total stroke.. .. .. Analysis 1.9. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 9 Fatal stroke.. .. .. . Analysis 1.10. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 10 Non-fatal stroke.. .. Analysis 1.11. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 11 Revascularization (HMG Co A Group / Statins

show abstract

The treatment of intermittent claudication with beta-pyridyl carbinol over two years

Cited by 6 publications

References 11 publications

Lipid-Lowering Therapy in Patients with Peripheral Arterial Disease

Lipid-Lowering Therapy in Patients with Peripheral Arterial Disease

Lipid-lowering for lower limb atherosclerosis

Lipid-lowering for peripheral arterial disease of the lower limb

Contact Info

Product

Resources

About